

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following document which is also listed on the attached Substitute Form PTO-1449 (**EXHIBIT A**) and a copy of which is attached hereto as **Exhibit 1**:

1. Communication of a Notice of Oppositions mailed July 18, 2007 in connection with related European Application No. 94900538.3, now European Patent No. 668777 granted October 11, 2006, as well as (A) opposition documents filed by BZL Biologics LLC including (1) a Notice of Opposition Form 2300 filed by BZL Biologics LLC; and (2) Statement of Grounds for Opposition and copies of references cited in the Grounds for Opposition ((i) EP 066877; (ii) WO94/09820; (iii) Holmes et al., 2001, Expert Opinion on Investigational Drugs, 10(3):544-519; and (iv) Schulke et al., 2003, PNAS, 100(22):12590-12595) and (B) opposition documents filed by Northwest Bio Therapeutics Inc. including a Notice of Opposition Form 2300 from Northwest Bio Therapeutics Inc.; and (2) Statement of Grounds for Opposition including a list of documents D1 through D36 (D1 through D28, D30-D32 and D36 of which are of record in the subject application; D26 being part of Exhibit 12 - *Communication Pursuant To Article 96(2) EPC, issued February 8, 2005 in connection with related European Patent Application No. 94 90 0538.3 - of the Supplemental Information Disclosure Statement filed April 4, 2005 in connection with the above-identified application*), copies of D28 through D36 of which are enclosed (D28 - Horoszewicz J. et al.,

1987, Anticancer Research 7:927-936; D29 - Horoszewicz J. et al., 1983, Cancer Research 43:1809-1818; D30 - Wright et al. (1990), Antibody, Immunoconjugates and Radiopharmaceuticals 3:39 (Abst#193); D31 - Axelrod et al., 1992, AUA 87th Annual Meeting, Abstract 596; D32 - Israeli et al. (1992), Proc. 83rd Ann. Meeting of the American Association for Cancer, 33:356 (Abstract); D33 - Declaration in the name of Julius S. Horoszewicz; D34 - Declaration in the name of John D. Rodwell; D35 - Declaration in the name of Paul Kaladas; D36 - U.S. Patent No. 5,162,504, issued November 10, 1992, Horoszewicz et al.)

This Supplemental Information Disclosure Statement is being submitted under 37 C.F.R. §1.97(d), and a check in the amount of ONE HUNDRED AND EIGHTY DOLLARS (\$180.00) is enclosed. In accordance with 37 C.F.R. §1.97(e)(1), the undersigned states that the document cited in the information disclosure statement was first received in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Supplemental Information Disclosure Statement.

Applicants request that the Examiner review the document listed above, a copy of which is attached hereto, and make it of record in the subject application.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

Applicants: Warren D.W. Heston, et al.
Serial No.: 10/614,625
Filed: July 2, 2003
Page 6 of 6



No fee, other than the enclosed total fee of \$240.00 including \$60.00 fee for a one-month extension of time and a \$180.00 fee for filing a Supplemental Information Disclosure Statement is deemed necessary in connection with the filing of this Amendment and Supplemental Information Disclosure Statement. However, if any additional fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,

John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313	
	9/13/07
John P. White	Date
Reg. No. 28,678	

Docket No. 41426-GC/JPW/BJAIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Warren D.W. Beston et al.
Serial No. : 10/614,625 Examiner: C. Borgeest
Filed : July 2, 2003 Group Art Unit: 1649
For : PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES THEREOF

Mail Stop Amendment
COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, VA 22313-1450

Date: September 13, 2007

Sir:

Transmitted herewith is an amendment to the above-identified application.

 x Small entity status of this application under 37 C.F.R. §1.9 and §1.27 has been previously established.

 A verified statement to establish small entity status under 37 C.F.R. §1.9 and §1.27 is enclosed.

 No additional fee is required.

The filing fee is calculated as follows:

	Number after Amendment	Highest Number Previously Paid For ¹	Number of Extra Claims Presented	RATE		FEE	
				Small Entity	Other Entity	Small Entity	Other Entity
Total Claims	1 - 20	=	*** 0 X	\$25	\$50	=	0.00
Independent Claims	1 - 3	=	*** 0 X	\$100	\$200	=	0.00
Multiple Dependent Claim(s) Presented For First Time Yes <u> x </u> No				\$180	\$360	=	0.00
				TOTAL ADDITIONAL FEE		\$ 0.00	

- ¹ The "HIGHEST NUMBER PREVIOUSLY PAID FOR" (Total or Independent) is the highest of the "NUMBER AFTER AMENDMENT" in any prior amendment or the number of claims originally filed.
- If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 20, write "20" in this space.
 - If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 3, write "3" in this space.
 - If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than "0", write "0".

Applicant(s): Warren D.W. Heston et al.

Serial No. : 10/614,625

Filed : July 2, 2003

Amendment Transmittal Letter

Page 2

The following are also enclosed:

☒ One additional copy of this Amendment Transmittal Letter

☒ Return Receipt Postcard

☒ An Information Disclosure Statement, including Form PTO-1449

(Copies of citations included: Yes ☒ No ☐

and a fee of \$ 180.00 included)

☒ A Petition for an Extension of Time, including a fee of

\$ 60.00 for a Petition for 1 Month(s) Extension of Time

Other (identify): _____ ; _____

THE TOTAL FEE DUE IS \$ 240.00.

☒ A check in the amount of \$ 240.00 is enclosed.

Please charge Deposit Account No. _____ in the amount of

\$ _____.

☒ The Commissioner is hereby authorized to charge any additional fees required or credit any overpayment to Deposit Account No. 03-3125 as follows:

☒ Fees under 37 C.F.R. \$1.16 for the presentation of extra claims

☒ Patent application processing fees under 37 C.F.R. \$1.17

Respectfully submitted,

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:
Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

John P. White 9/13/07
Reg. No. 28,678

Date

John P. White
John P. White
Registration No. 28,678
Attorney for Applicant(s)
Cooper & Dunham LLP (Customer #23432)
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

Form PTO-1449 Substitute	U.S. Department of Commerce Patent and Trademark Office	Application Number	10/614,625
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Filing Date	July 2, 2003
		First Named Inventor	Warren D.W. Heston et al.
		Art Unit	1649
		Examiner Name	C. Borgeest
		Attorney Docket No.	41426-GC/JPW/BJA

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		<p>Communication of a Notice of Oppositions mailed July 18, 2007 in connection with related European Application No. 94900538.3, now European Patent No. 668777 granted October 11, 2006, as well as (A) opposition documents filed by BZL Biologics LLC including (1) a Notice of Opposition Form 2300 filed by BZL Biologics LLC; and (2) Statement of Grounds for Opposition and copies of references cited in the Grounds for Opposition ((i) EP 066877; (ii) WO94/09820; (iii) Holmes et al., 2001, Expert Opinion on Investigational Drugs, 10(3):544-519; and (iv) Schulke et al., 2003, PNAS, 100(22):12590-12595) and (B) opposition documents filed by Northwest Bio Therapeutics Inc. including a Notice of Opposition Form 2300 from Northwest Bio Therapeutics Inc.; and (2) Statement of Grounds for Opposition including a list of documents D1 through D36 (D1 through D28, D30-D32 and D36 of which are of record in the subject application; D26 being part of Exhibit 12 - Communication Pursuant To Article 96(2) EPC, issued February 8, 2005 in connection with related European Patent Application No. 94 90 0538.3 - of the Supplemental Information Disclosure Statement filed April 4, 2005 in connection with the above-identified application), copies of D28 through D36 of which are enclosed (D28 - Horoszewicz J. et al., 1987, Anticancer Research 7:927-936; D29 - Horoszewicz J. et al., 1983, Cancer Research 43:1809-1818; D30 - Wright et al. (1990), Antibody, Immunoconjugates and Radiopharmaceuticals 3:39 (Abst#193); D31 - Axelrod et al., 1992, AUA 87th Annual Meeting, Abstract 596; D32 - Israeli et al. (1992), Proc. 83rd Ann. Meeting of the American Association for Cancer, 33:356 (Abstract); D33 - Declaration in the name of Julius S. Horoszewicz; D34 - Declaration in the name of John D. Rodwell; D35 - Declaration in the name of Paul Kaladas; D36 - U.S. Patent No. 5,162,504, issued November 10, 1992, Horoszewicz et al.)</p>	

EXAMINER
SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.

Applicants: Warren D.W. Heston et al.
 Serial No.: 10/614,625
 Filed: July 2, 2003
 Exhibit A